Open AccessAnterior resection syndrome: a randomized clinical trial of a 5-HT3 receptor antagonist (ramosetron) in male patients with rectal cancer
Author(s) -
SeungBum Ryoo,
Jong-Wan Park,
D W Lee,
Min-Chae Lee,
YeaLa Kwon,
M J Kim,
Sung Ho Moon,
SeungYong Jeong,
K J Park
Publication year - 2021
Publication title -
british journal of surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.202
H-Index - 201
eISSN - 1365-2168
pISSN - 0007-1323
DOI - 10.1093/bjs/znab071
Subject(s) - medicine , colorectal cancer , randomized controlled trial , antagonist , regorafenib , 5 ht3 receptor , surgery , cancer , oncology , receptor , 5 ht receptor , serotonin
No effective treatment exists for anterior resection syndrome (ARS) following sphincter-saving surgery for rectal cancer. This RCT assessed the safety and efficacy of a 5-HT3 receptor antagonist, ramosetron, for ARS.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom